{"PubmedArticle": [{"MedlineCitation": {"SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "OtherAbstract": [], "CitationSubset": ["IM"], "KeywordList": [], "GeneralNote": [], "PMID": "17048576", "DateCompleted": {"Year": "2007", "Month": "09", "Day": "12"}, "DateRevised": {"Year": "2018", "Month": "12", "Day": "01"}, "Article": {"ArticleDate": [], "Language": ["chi"], "ELocationID": [], "Journal": {"ISSN": "1001-5302", "JournalIssue": {"Volume": "31", "Issue": "15", "PubDate": {"Year": "2006", "Month": "Aug"}}, "Title": "Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica", "ISOAbbreviation": "Zhongguo Zhong Yao Za Zhi"}, "ArticleTitle": "[Study on chronical hepatitis B with treatment of integrative traditional Chinese and Western medicine].", "Pagination": {"StartPage": "1277", "EndPage": "1280", "MedlinePgn": "1277-80"}, "Abstract": {"AbstractText": ["To study curative effect of chronical hepatitis B with treatment of integrative traditional Chinese and western medicine.", "115 cases of HBeAg and/or HBVDNA positive chronical hepatitis B were randomly divided into two groups in control. The first group treated by traditional Chinese medicine (TCM)-Fufang Huangqi granule and the second treated by intergrative traditional Chinese and western medicine (ICWM)-Fufang Huangqi granule and lamivudine for at least 24 weeks.", "The positive rate of HBVDNA at 12, 24 weeks, and the positive rate of HBeAg at 24 weeks in TCM are markedly lower than those of before treatment (P < 0.01). The positive rate of HBeAg and the positive rate of HBVDNA in ICWM are markedly lower than those of before treatment both at 12, 24 weeks (P < 0.01). The average values of HBVDNA are markly lower than before treatment in two groups at both 12,24 weeks (P < 0.01). At 12 weeks, the negative-turning rate of HBVDNA in the ICWM group is 79.17%, which shows significant difference in comparision with 40.00% in the TCM group (P < 0.01). The negative-turning rate of HBeAg in the ICWM group is 26.92%, which shows no significant difference in comparision with 32. 08% in the TCM group. At 24 weeks, the negative-turning rate of HBVDNA in the ICWM group is 85.71%, which shows significant difference in comparision with 50.00% in the TCM group (P < 0.01). The negative-turning rate of HBeAg in the ICWM group is 36.36%, which shows no significant difference in comparision with 28.57% in the TCM group. At 12 weeks,the total effective rate of the ICWM group is 96. 43%, which shows significant difference in comparision with 71.26% in the TCM group (P<0.01). At 24 weeks, the total effective rate of the ICWM group is 88. 00%, which shows significant difference in comparision with 67.61 % in the TCM group (P < 0.01). The average values of ALT and AST are markly improved than those of before treatment in two groups (P < 0.01). The average values of ALB is markly higher than before in TCM groups after 24 weeks treatment (P < 0.01).", "Fufang Huangqi granule integrated with lamivudine possesses a better effect for counteracting the hepatitis B virus and improving the liver functioin than only itself."]}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "302 Hospital of PLA, Beijing, China."}], "Identifier": [], "LastName": "Yang", "ForeName": "Hui-yin", "Initials": "HY"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Li", "ForeName": "Jun", "Initials": "J"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Yi", "ForeName": "Mao", "Initials": "M"}], "PublicationTypeList": ["Journal Article", "Randomized Controlled Trial"]}, "MedlineJournalInfo": {"Country": "China", "MedlineTA": "Zhongguo Zhong Yao Za Zhi", "NlmUniqueID": "8913656", "ISSNLinking": "1001-5302"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Albumins"}, {"RegistryNumber": "0", "NameOfSubstance": "Anti-HIV Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "DNA, Viral"}, {"RegistryNumber": "0", "NameOfSubstance": "Drug Combinations"}, {"RegistryNumber": "0", "NameOfSubstance": "Drugs, Chinese Herbal"}, {"RegistryNumber": "0", "NameOfSubstance": "Hepatitis B e Antigens"}, {"RegistryNumber": "2T8Q726O95", "NameOfSubstance": "Lamivudine"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Adolescent"}, {"QualifierName": [], "DescriptorName": "Adult"}, {"QualifierName": [], "DescriptorName": "Aged"}, {"QualifierName": ["metabolism"], "DescriptorName": "Albumins"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Anti-HIV Agents"}, {"QualifierName": ["chemistry"], "DescriptorName": "Astragalus propinquus"}, {"QualifierName": ["blood"], "DescriptorName": "DNA, Viral"}, {"QualifierName": [], "DescriptorName": "Drug Combinations"}, {"QualifierName": [], "DescriptorName": "Drug Synergism"}, {"QualifierName": ["isolation & purification", "therapeutic use"], "DescriptorName": "Drugs, Chinese Herbal"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": ["blood"], "DescriptorName": "Hepatitis B e Antigens"}, {"QualifierName": ["genetics"], "DescriptorName": "Hepatitis B virus"}, {"QualifierName": ["blood", "drug therapy"], "DescriptorName": "Hepatitis B, Chronic"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Lamivudine"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Middle Aged"}, {"QualifierName": ["chemistry"], "DescriptorName": "Plants, Medicinal"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2006", "Month": "10", "Day": "20", "Hour": "9", "Minute": "0"}, {"Year": "2007", "Month": "9", "Day": "13", "Hour": "9", "Minute": "0"}, {"Year": "2006", "Month": "10", "Day": "20", "Hour": "9", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["17048576"]}}], "PubmedBookArticle": []}